Human PLAC9 ELISA

INTENDED USE:
For the quantitative determination of human PLAC9 concentrations in serum, plasma or cell culture supernate samples

INTRODUCTION:
Placenta-specific protein 9 (PLAC9) is a putative secreted protein highly enriched in placenta. It plays a major role in embryonic development. During human embryogenesis, PLAC9 levels were upregulated at 8-9 weeks. PLAC9 was found to be involved in protein interactions in human liver. Overexpression of PLAC9 inhibited cell proliferation capacity in hepatic cells by modifying cell cycle related proteins.

PRINCIPLE OF THE ASSAY:
This assay is a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). The microtiter plate is pre-coated with a rabbit polyclonal antibody specific for human PLAC9. Standards and samples are pipetted into the wells and any human PLAC9 present is bound by the immobilized antibody. After washing away any unbound substances, a biotin labelled polyclonal antibody specific for human PLAC9 is added to the wells. After wash step to remove any unbound reagents, streptavidin-HRP conjugate (STP-HRP) is added. After the last wash step, an HRP substrate solution is added and colour develops in proportion to the amount of human PLAC9 bound initially. The assay is stopped, and the optical density of the wells determined using a microplate reader. Since the increases in absorbance are directly proportional to the amount of captured human PLAC9, the unknown sample concentration can be interpolated from a reference curve included in each assay.

SENSITIVITY: The lowest level of human PLAC9 that can be detected by this assay is 0.156 ng/mL

PUBLICATIONS CITING THIS PRODUCT